Earnings Release • Aug 14, 2014
Earnings Release
Open in ViewerOpens in native device viewer
August 14, 2014
Sales growth in the first half was in line with expectations, within the range for full-year outlook. Organically, sales grew by 8% (4% DKK, 8% LCY). Sales growth slowed down during the period as expected after a strong first quarter and due to a higher comparable level in the second quarter.
EBIT grew by 19%, and the EBIT margin increased by 3.5 percentage points to 28.1%. The higher EBIT margin was driven by a one-time positive impact of roughly 2 percentage points from The BioAg Alliance and a significant improvement in underlying earnings. Free cash flow came in strongly at DKK 3,417 million due to the positive one-time impact from The BioAg Alliance and a relatively low level of CAPEX in the period.
The full-year sales growth outlook is maintained. Full-year expectations for EBIT and net profit growth are increased to 9-11%, up from 8-10%. Expectations for ROIC, including goodwill, are adjusted to ~22%, up from 21-22%. Lastly, expectations for free cash flow are revised upward by DKK 500 million, mainly as a result of lower expectations for net investments and a higher positive impact from The BioAg Alliance.
| Realized | 2014 outlook | 2014 outlook | ||
|---|---|---|---|---|
| 1H 2014 | 1H 2013 | August 14* | April 24 | |
| Sales, DKKm | 6,094 | 5,870 | ||
| Sales growth, DKK | 4% | 5% | 4-6% | 4-6% |
| Sales growth, LCY | 8% | 6% | 6-9% | 6-9% |
| Sales growth, organic | 8% | 6% | 6-9% | 6-9% |
| Gross margin | 57.8% | 57.7% | ||
| EBIT, DKKm | 1,710 | 1,443 | ||
| EBIT growth | 19% | 7% | 9-11% | 8-10% |
| EBIT margin | 28.1% | 24.6% | ~26% | ~26% |
| Net profit, DKKm | 1,285 | 1,070 | ||
| Net profit growth | 20% | 7% | 9-11% | 8-10% |
| Net investments excl. acquisitions and The BioAg Alliance impact, DKKm |
206 | 352 | 700-800 | 900-1,000 |
| Free cash flow before acquisitions, DKKm | 3,417 | 660 | 3,800-3,900 | 3,300-3,400 |
| ROIC (including goodwill) | 24.6% | 19.3% | ~22% | 21-22% |
| Avg. USD/DKK | 544 | 568 | 551 | 541 |
| EPS, DKK | 4.09 | 3.41 | ||
| EPS (diluted), DKK | 4.05 | 3.37 |
* Assumes exchange rates for the company's key currencies remain at the closing rates on August 13 for the rest of 2014.
The outlook includes the impact from the agreement with Monsanto on The BioAg Alliance.
"It's been a good first half for Novozymes. Sales growth was in line with expectations and earnings were strong. For the full year, we maintain our outlook for sales growth, and profit is now expected to come in a little better than what we thought back in April. Looking beyond the financial performance, we've seen good progress in our innovation pipeline and portfolio of growth platforms in the first half of the year. In the second half, we'll continue to concentrate our efforts on advancing both to further strengthen our ability to deliver double-digit sales growth."
Company announcement No. 56, 2014 Page 1 of 18
Novozymes A/S Investor Relations CVR number: 10 00 71 27 2014-11411-01
Krogshoejvej 36 2880 Bagsvaerd Denmark
Telephone: +45 4446 0000 Email: [email protected] Internet: www.novozymes.com
Total sales: DKK: +4% LCY: +8% Organic: +8% Total sales in the first half of 2014 were DKK 6,094 million, an increase of 4% compared with the first half of 2013. Exchange rates had a negative impact on sales, and sales in LCY were up by 8%. Acquisitions and The BioAg Alliance had a minor impact on sales growth and, organically, sales grew by 8%. Sales to the Bioenergy industry were the most significant contributor to sales growth.
Household Care: DKK: +2% LCY: +5% Sales to the Household Care industry increased by 2% in DKK and by 5% in LCY compared with the first half of 2013. Growth was driven by increased enzyme penetration across detergent tiers to enhance wash performance, enable low-temperature washing and replace traditional chemicals in detergent formulations.
Sales in emerging markets were a significant contributor to the global sales growth despite weakness in China. Sales in developed markets also contributed positively to sales growth, but were hampered by a competitive detergent market with shifts in market shares between top- and mid-tier detergents. New innovation is expected to support growth in the second half of the year.
Food & Beverages: DKK: +2% LCY: +5% Sales to the Food & Beverages industries increased by 2% in DKK and by 5% in LCY compared with the first half of 2013. Sales for the production of healthy foods and to the baking industry were the most significant growth contributors. Despite relatively flat sales for freshkeeping applications, sales to the baking industry grew as a result of good growth in other application areas. Sales to the starch industry were flat for the period, as the important Chinese starch market remained challenging.
Bioenergy: DKK: +20% LCY: +26% Sales to the Bioenergy industry were up by 20% in DKK and by 26% in LCY compared with the first half of 2013. The U.S. Energy Information Administration estimates that U.S. ethanol production in the first half of 2014 grew by ~9% compared with the same period last year.
Bioenergy sales benefited from continued positive developments in Novozymes' yield discovery solutions Avantec® , Spirizyme® Achieve and Olexa ® . Penetration of all three solutions continued to increase in the first half of 2014, albeit at a more modest level toward the latter part of the period. About one-third of U.S. ethanol is now produced with one or more of these novel solutions.
Agriculture & Feed: DKK: (3)% LCY: +2% Sales to the Agriculture & Feed industries decreased by 3% in DKK and were up by 2% in LCY compared with the first half of 2013. Organically, sales grew by 4%. Sales to the animal feed industry developed well and contributed positively to sales growth. Sales to the animal feed industry increased as a result of good performance across product categories, especially in the Americas.
Sales to the BioAg industry were slightly lower organically compared with the same period last year, due to an expected shift in timing of sales with one specific customer from the first half of 2013 to the second half of 2014.
In the first half of 2014, following the change in revenue recognition in BioAg, Novozymes recognized a total of DKK 144 million of deferred income as revenue (DKK 62 million in Q1 and DKK 82 million in Q2).
Technical & Pharma: DKK: +1% LCY: +3% Sales to the Technical & Pharma industries increased by 1% in DKK and by 3% in LCY compared with the first half of 2013. Sales of enzyme solutions for the manufacture of pharmaceutical ingredients were the main driver of sales growth, while sales to the textile and leather industries were flat.
Europe/MEA: DKK: +4% LCY: +5% Sales in Europe, the Middle East & Africa (Europe/MEA) grew by 4% in DKK and by 5% in LCY compared with the first half of 2013. Sales to the Household Care and Food & Beverages industries were the most significant growth drivers. Sales to the Agriculture & Feed industries were lower compared with the same period last year due to timing of BioAg sales.
North America: DKK: +6% LCY: +11% Sales in North America increased by 6% in DKK and by 11% in LCY compared with the first half of 2013. Sales to the Bioenergy and Agriculture & Feed industries were the main growth drivers, whereas sales to the Food & Beverages industries were slightly lower than in 1H 2013.
Asia Pacific: DKK: (4)% LCY: +2% Sales in Asia Pacific were down by 4% in DKK and up by 2% in LCY compared with the first half of 2013. Sales to the Household Care and Bioenergy industries were the main contributors to sales growth, whereas sales to the Technical & Pharma industries were lower. Broadly speaking, China was a challenging market in the first half, among other things due to the continued tough market environment for starch conversion.
Latin America: DKK: +8% LCY: +18% Sales in Latin America were up by 8% in DKK and by 18% in LCY compared with the first half of 2013. All industries contributed to the strong sales growth. Household Care was the most significant growth contributor.
Total costs: +4% Total costs excluding net financials and tax were DKK 4,592 million, up 4% compared with the first six months of 2013. The increase in total costs was driven equally by higher production costs and higher operating costs.
Total production costs increased by 3% compared with the same period last year. Production costs increased mainly due to a higher activity level throughout the period, and the write-downs and accelerated depreciation and amortization realized in the first quarter of 2014.
Operating costs increased by 4% to DKK 2,023 million. The ratio of operating costs to sales was 33%, on par with the same period last year.
Sales and distribution costs decreased as sales and marketing responsibility and costs were transferred to Monsanto on completion of The BioAg Alliance agreement. The positive impact from this BioAg transfer of sales and marketing costs to Monsanto more than offset higher costs from the higher activity level.
The increase in R&D costs was driven primarily by the higher activity level coupled with the write-downs and accelerated depreciation and amortization realized in the first quarter of 2014.
Other operating income: DKK 208 million Other operating income was DKK 208 million, up from DKK 3 million in the first half of 2013. This increase was primarily driven by the one-time realized gain from the transfer of predominantly intangible assets to Monsanto on completion of The BioAg Alliance agreement in the first quarter of 2014. All of the other operating income realized in the second quarter of 2014 was unrelated to The BioAg Alliance.
Depreciation and amortization increased to DKK 468 million in the first half of 2014, up from DKK 367 million in the same period last year. The increase was driven equally by the write-downs and accelerated depreciation and amortization of DKK 50 million realized in the first quarter of 2014 and a higher level of depreciation and amortization.
EBIT: +19% EBIT grew by 19% to DKK 1,710 million, up from DKK 1,443 million in the first half of 2013, driven primarily by The BioAg Alliance agreement, continued productivity improvements and favorable product mix changes.
EBIT margin: 28.1% The EBIT margin was 28.1%, an increase of 3.5 percentage points from 24.6% in the first half of 2013. The net positive impact from The BioAg Alliance agreement on EBIT margin in the first half was roughly 2 percentage points.
The underlying EBIT margin increased by around 1.5 percentage points to around 26%. Continued productivity improvements across the organization, a favorable development in product mix and higher other operating income drove the EBIT margin higher despite an unfavorable development in currency exchange rates compared with the same period last year.
Net financial costs: DKK 41 million Net financial costs were DKK 41 million, down from DKK 102 million in the first half of 2013. The decrease was mainly a result of a DKK 29 million gain on net currency hedging/revaluation compared with a loss of DKK 45 million in the same period last year.
Profit before tax was DKK 1,669 million, an increase of 24% from the first half of 2013.
Operating cash flow: DKK 3,204 million Cash flow from operating activities was DKK 3,204 million in the first half of 2014, up from DKK 1,012 million in the same period last year. The higher operating cash flow was mainly a result of The BioAg Alliance agreement coupled with a favorable development in net working capital and higher net profit. Deferred income of DKK 1,261 million received through The BioAg Alliance is recognized as a liability and impacts the operating cash flow as a positive change in net working capital.
Net investments excl. acq.: DKK (213) million Net investments excluding acquisitions were negative at DKK 213 million, compared with net investments of DKK 352 million in the first half of 2013. Net investments were negative as the transfer of assets to Monsanto as part of The BioAg Alliance agreement more than offset a relatively low level of CAPEX in the first half of 2014. Excluding the impact from The BioAg Alliance asset transfer to Monsanto, net investments were DKK 206 million in the period.
Free cash flow before acq.: DKK 3,417 million Free cash flow before acquisitions was DKK 3,417 million, up from DKK 660 million in the first half of 2013. The free cash flow was positively affected by the increase in operating cash flow and the negative net investments – both driven by the completion of The BioAg Alliance.
Shareholders' equity decreased by 2% to DKK 10,833 million at June 30, 2014, compared with DKK 11,066 million at year-end 2013. Shareholders' equity decreased due to dividend payments and purchase of treasury stock, which more than offset the positive contribution from comprehensive income.
Equity ratio: 59% Shareholders' equity represented 59% of the balance sheet total, down from 67% at year-end 2013.
Net interestbearing debt: DKK (961) million Novozymes is free of debt on a net basis, with a positive net interest-bearing debt balance of DKK 961 million at June 30, 2014, compared with negative net interest-bearing debt of DKK 805 million at December 31, 2013. The BioAg Alliance agreement was the main driver in Novozymes becoming net cash positive. Cash flow from operating activities and negative net investments impacted net debt positively, whereas dividend payouts of DKK 788 million and net purchase of treasury stock of DKK 805 million had a negative impact on net interest-bearing debt.
Net debt-to-equity was (9)% at June 30, 2014, down from 7% at December 31, 2013.
ROIC: 24.6% Return on invested capital (ROIC), including goodwill, was 24.6%, up 5.3 percentage points from 19.3% in the first half of 2013. The extraordinary increase in ROIC was a result of higher net profit and lower average invested capital. The invested capital decreased as a result of negative net investments, depreciation and amortization, and lower net working capital driven by the deferred income from The BioAg Alliance agreement.
Treasury stock: 2.4% At June 30, 2014, the holding of treasury stock was 7.5 million B shares, equivalent to 2.4% of the common stock. Year-to-date June 30, 2014, Novozymes had repurchased 3.4 million shares worth approximately DKK 859 million within the expected DKK 2,000 million stock buyback program in 2014.
All resource efficiency measurements improved in the first half of 2014 and targets for the full year 2014 are on track to be met. On the social side, the organization realized a drop in the rate of both occupational accidents and absence, and is on track to reach the 2014 targets here too.
| 1H 2014 | 1H 2013 | 2014 target | |
|---|---|---|---|
| Water efficiency (compared with 2005) | 34% | 31% | 34% |
| Energy efficiency (compared with 2005) | 42% | 36% | 42% |
| CO2 efficiency (compared with 2005) | 55% | 53% | >50% |
| Occupational accidents per million working hours | 1.4 | 1.9 | <3.0 |
| Number of employees on June 30 | 6,205 | 6,149 | - |
| Rate of employee turnover | 8.4% | 7.6% | 4-9% |
| Rate of absence | 1.8% | 1.9% | <3% |
| 2014 outlook August 14* |
2014 outlook April 24 |
2014 outlook January 21 |
|
|---|---|---|---|
| Sales growth, DKK | 4-6% | 4-6% | 4-7% |
| Sales growth, LCY | 6-9% | 6-9% | 6-9% |
| Sales growth, organic | 6-9% | 6-9% | 6-9% |
| EBIT growth | 9-11% | 8-10% | 6-9% |
| EBIT margin | ~26% | ~26% | 25-26% |
| Net profit growth | 9-11% | 8-10% | 6-9% |
| Net investments excl. acquisitions and The BioAg Alliance impact, DKKm |
700-800 | 900-1,000 | 900-1,100 |
| Free cash flow before acquisitions, DKKm | 3,800-3,900 | 3,300-3,400 | 3,200-3,300 |
| ROIC (including goodwill) | ~22% | 21-22% | ~21% |
| Avg. USD/DKK | 551 | 541 | 550 |
| * Assumes exchange rates for the company's key currencies remain at the closing rates on August 13 for the rest of 2014. |
The outlook includes the impact from the agreement with Monsanto on The BioAg Alliance.
Monsanto impact included in 2014 outlook Sales growth: Organic: 6-9% LCY: 6-9% DKK: 4-6% On February 10, 2014, The BioAg Alliance agreement with Monsanto was completed. The financial outlook for 2014 includes the expected financial impact from the agreement. Disregarding the impact from The BioAg Alliance, the business delivered a good first half. Sales growth was in line with expectations, within the range for full-year outlook, and underlying earnings developed strongly. Sales growth decreased throughout the period as expected, partly due to a strong first quarter of 2014 and a higher comparable level in the second quarter. Sales developed in line with expectations in the first half of 2014, and the full-year organic sales growth outlook is maintained at 6-9% (LCY 6-9%). Based on exchange rates at August 13, 2014, full-year sales growth in DKK is also still expected to be 4-6%.
Novozymes continues to expect a positive contribution to sales growth from all five sales areas. Of these, Bioenergy is expected to be the most significant growth contributor.
Household Care sales are expected to be driven by a continued desire by customers to improve wash performance, enable low-temperature washing and replace chemicals. Emerging markets are expected to contribute significantly to sales growth. Developed markets are also expected to contribute positively to sales growth, albeit at a lower level than previously expected. New innovation is expected to support growth in the second half of the year, and Household Care organic sales growth for the full year is expected on level with that of the first half of 2014.
Food & Beverages sales growth is expected to be driven by further growth in solutions for the production of healthy foods. Sales to the baking industry are also expected to contribute to growth, whereas sales for starch conversion are now expected to be roughly flat given the continued difficult conditions on the Chinese starch market.
Bioenergy sales are expected to benefit from increased penetration of Novozymes' yield discovery solutions Avantec® , Spirizyme® Achieve and Olexa® . The 2014 sales outlook is now based on the expectation that U.S. fuel ethanol production in 2014 will be just above 14 billion gallons, up from the previously expected ~13.5 billion gallons.
Technical & Pharma sales are still expected to grow, primarily due to an expected increase in pharma sales.
On February 10, 2014, Novozymes' BioAg sales recognition changed to reflect the equal value share with Monsanto. In 2014, the lower sales recognition is still expected to be partly counterbalanced by DKK ~200 million in deferred income, of which DKK 144 million was recognized as sales in the first half of 2014.
Agriculture & Feed sales in DKK and LCY are still expected to be impacted negatively by up to 7 percentage points net in 2014 (up to 1% of total group sales). The positive contribution to sales growth from TJ Technologies, which was acquired in June 2013, is still expected to offset about half of the above 7 percentage points, resulting in a net negative impact from acquisitions and divestments on Agriculture & Feed sales in DKK and LCY of 3-4 percentage points.
Organically, BioAg sales are expected to deliver good underlying growth across regions, albeit at a slightly lower level in North America than previously expected following the weaker growth in offtake due to the late planting season. Feed sales have developed well in the first half of the year and are expected to continue to develop well for the remainder of the year, despite the continued tough competitive situation within phytase enzymes.
The net impact on Novozymes' gross margin in 2014 of Novozymes and Monsanto splitting revenue and of the deferred income remains an expected negative impact of around 1 percentage point.
Total sales and distribution costs as a percentage of sales for Novozymes are also still expected to decrease by around 1 percentage point, given the transfer of marketing responsibility to Monsanto. This roughly evens out the negative impact from the lower gross margin.
In the first quarter of 2014, Novozymes realized a one-time gain from the transfer of predominantly intangible assets to Monsanto, as the transaction value of the assets exceeded the book value. The positive contribution to the EBIT margin in 2014, net of transaction costs, transition costs and increased R&D spend in 2014, is still expected at 0.5-1 percentage point, as operational costs materialize throughout 2014.
Net profit Net profit is now expected to grow by 9-11% due to the higher EBIT growth.
growth: 9-11% Around 75% of expected USD/DKK exposure for 2014 has been hedged at 5.79 USD/DKK. In 2013, the full USD/DKK exposure was hedged at 5.63.
The free cash flow includes a positive impact from The BioAg Alliance agreement, of now more than DKK 1,500 million, up from DKK 1,350 million at previous guidance. The main reason for the higher impact from The BioAg Alliance is a temporary reduction in net working capital.
ROIC: ~22% Return on invested capital is adjusted to ~22%, up from 21-22% at previous guidance, following increased expectations for net profit. This includes a positive impact from The BioAg Alliance of around 1.5 percentage points.
The outlook is based on exchange rates for the company's key currencies remaining at the closing rates on August 13, 2014, for the full year.
| (DKK) | EUR | USD | BRL | CNY |
|---|---|---|---|---|
| Average exchange rate 2013 | 746 | 562 | 262 | 91 |
| Average exchange rate 1H 2013 | 746 | 568 | 280 | 92 |
| Average exchange rate 1H 2014 | 746 | 544 | 237 | 88 |
| Closing rate August 13, 2014 | 746 | 558 | 245 | 91 |
| Estimated average exchange rate 2014* | 746 | 551 | 241 | 89 |
| Change in estimated exchange rate 2014 compared with average exchange rate 2013 |
0% | -2% | -8% | -2% |
* Estimated average exchange rate is calculated as the average exchange rate YTD combined with the closing rate Aug. 13 for the rest of 2014.
Other things being equal, a 5% movement in the USD is expected to have an annual impact on EBIT of DKK 70-90 million.
The following sustainability expectations are included in the outlook for 2014:
Keep the frequency of occupational accidents below 3.0 per million working hours
Keep employee turnover between 4% and 9%
The Interim report for the first half of 2014 has been prepared in accordance with IAS 34 and the additional Danish regulations for the presentation of quarterly interim reports by listed companies. The Interim report for the first half of 2014 follows the same accounting policies as the annual report for 2013, except for all new, amended or revised accounting standards and interpretations (IFRSs) endorsed by the EU effective for the accounting period beginning on January 1, 2014. These IFRSs have not had any material impact on the Group's interim report.
This company announcement contains forward-looking statements, including the financial outlook for 2014. Forward-looking statements are, by their very nature, associated with risks and uncertainties that may cause actual results to differ materially from expectations. The uncertainties may include unexpected developments in the international currency exchange and securities markets, market-driven price decreases for Novozymes' products, and the launch of competing products in Novozymes' core areas.
Poonam Kapila (India) +91 991 082 2339 [email protected]
The Board of Directors and the Executive Leadership Team have considered and approved the Interim report for Novozymes A/S for the first half of 2014. The interim report has not been audited or reviewed by the company's independent auditor.
The Interim report for the first half of 2014 has been prepared in accordance with IAS 34 and the additional Danish regulations for the presentation of quarterly interim reports by listed companies.
In our opinion the accounting policies used are appropriate, the Group's internal controls relevant to preparation and presentation of an interim report are adequate, and the Interim report gives a true and fair view of the Group's assets, liabilities, net profit and financial position at June 30, 2014, and of the results of the Group's operations and cash flow for the first half of 2014.
We further consider that the Management review in the preceding pages gives a true and fair view of the development in the Group's activities and business, the profit for the period and the Group's financial position as a whole, and a description of the most significant risks and uncertainties to which the Group is subject.
Bagsvaerd, August 14, 2014
| Peder Holk Nielsen President & CEO |
Benny D. Loft | Per Falholt |
|---|---|---|
| Andrew Fordyce | Thomas Nagy | Thomas Videbæk |
| Board of Directors | ||
| Henrik Gürtler Chairman |
Agnete Raaschou-Nielsen Vice Chairman |
Mathias Uhlén |
| Anders Hentze Knudsen | Lars Bo Køppler | Lena Bech Holskov |
| Lena Olving | Lars Green | Jørgen Buhl Rasmussen |
| Appendix 1 | Main items and key figures |
|---|---|
| 1.1 Key figures | |
| 1.2 Income statement | |
| 1.3 Statement of comprehensive income | |
| Appendix 2 | Distribution of revenue |
| 2.1 By industry | |
| 2.2 By geography | |
| Appendix 3 | Statement of cash flows |
| Appendix 4 | Balance sheet and Statement of shareholders' equity |
| 4.1 Balance sheet | |
| 4.2 Statement of shareholders' equity | |
| Appendix 5 | Product launches in 2014 |
| Appendix 6 | Company announcements for the fiscal year 2014 (excluding management's trading in Novozymes shares, major shareholder announcements and share buyback status) |
| Appendix 7 | Financial calendar |
| (DKK million) | 1H 2014 | 1H 2013 | % change | Q2 2014 | Q2 2013 | % change |
|---|---|---|---|---|---|---|
| Revenue | 6,094 | 5,870 | 4% | 3,061 | 3,025 | 1% |
| Gross profit | 3,525 | 3,387 | 4% | 1,771 | 1,732 | 2% |
| Gross margin | 57.8% | 57.7% | 57.9% | 57.3% | ||
| EBITDA | 2,178 | 1,810 | 20% | 1,011 | 926 | 9% |
| EBITDA margin | 35.7% | 30.8% | 33.0% | 30.6% | ||
| Operating profit / EBIT | 1,710 | 1,443 | 19% | 787 | 734 | 7% |
| EBIT margin | 28.1% | 24.6% | 25.7% | 24.3% | ||
| Net financials | (41) | (102) | (20) | (54) | ||
| Profit before tax | 1,669 | 1,341 | 24% | 767 | 680 | 13% |
| Tax | 384 | 271 | 42% | 176 | 124 | 42% |
| Net profit | 1,285 | 1,070 | 20% | 591 | 556 | 6% |
| Earnings per DKK 2 share | 4.09 | 3.41 | 20% | 1.89 | 1.77 | 7% |
| Earnings per DKK 2 share (diluted) |
4.05 | 3.37 | 20% | 1.87 | 1.75 | 7% |
| Net investments Free cash flow before |
(213) | 352 | ||||
| acquisitions | 3,417 | 660 | ||||
| Return on invested capital after tax (ROIC), incl. goodwill |
24.6% | 19.3% | ||||
| Net interest-bearing debt | (961) | 1,888 | ||||
| Equity ratio | 59.5% | 62.5% | ||||
| Return on equity | 23.5% | 21.8% | ||||
| Debt-to-equity ratio | (8.9)% | 18.8% |
| (DKK million) | 1H 2014 | 1H 2013 | Q2 2014 | Q2 2013 |
|---|---|---|---|---|
| Revenue Cost of goods sold |
6,094 2,569 |
5,870 2,483 |
3,061 1,290 |
3,025 1,293 |
| Gross profit | 3,525 | 3,387 | 1,771 | 1,732 |
| Sales and distribution costs Research and development costs |
742 862 |
761 776 |
363 441 |
381 404 |
| Administrative costs | 419 | 410 | 212 | 215 |
| Other operating income, net | 208 | 3 | 32 | 2 |
| Operating profit / EBIT | 1,710 | 1,443 | 787 | 734 |
| Net financials | (41) | (102) | (20) | (54) |
| Profit before tax | 1,669 | 1,341 | 767 | 680 |
| Tax | 384 | 271 | 176 | 124 |
| Net profit | 1,285 | 1,070 | 591 | 556 |
| Attributable to | ||||
| Shareholders in Novozymes A/S | 1,284 | 1,069 | 591 | 555 |
| Non-controlling interests | 1 | 1 | - | 1 |
| Details of net financials | ||||
| Foreign exchange gain/(loss), net | 29 | (45) | 26 | (24) |
| Interest income/(costs) | (24) | (23) | (11) | (17) |
| Other financial items | (46) | (34) | (35) | (13) |
| Net financials | (41) | (102) | (20) | (54) |
| Earnings per DKK 2 share | 4.09 | 3.41 | 1.89 | 1.77 |
| Average no. of A/B shares outstanding (million) | 313.9 | 313.4 | 313.1 | 313.8 |
| Earnings per DKK 2 share (diluted) | 4.05 | 3.37 | 1.87 | 1.75 |
| Average no. of A/B shares, diluted (million) | 317.2 | 317.1 | 316.3 | 317.2 |
| 1.3 Statement of comprehensive income | ||||
| (DKK million) | 1H 2014 | 1H 2013 | Q2 2014 | Q2 2013 |
| Net profit | 1,285 | 1,070 | 591 | 556 |
| Currency translation of subsidiaries and non | ||||
| controlling interests | (10) | (71) | 78 | (193) |
| Tax on currency translation adjustments | 1 | - | (1) | - |
| Currency translation adjustments | (9) | (71) | 77 | (193) |
| Cash flow hedges | ||||
| Fair value adjustments of cash flow hedges | (10) | (7) | (6) | 21 |
| Fair value adjustments reclassified to Financial | ||||
| income/costs | (36) | 21 | (20) | 13 |
| Tax on value adjustments of hedging instruments | 10 | (4) | 5 | (9) |
| Cash flow hedges | (36) | 10 | (21) | 25 |
| Other comprehensive income | (45) | (61) | 56 | (168) |
| Comprehensive income | 1,240 | 1,009 | 647 | 388 |
| Attributable to | ||||
| Shareholders in Novozymes A/S | 1,239 | 1,008 | 647 | 387 |
| Non-controlling interests | 1 | 1 | - | 1 |
| (DKK million) | 1H 2014 | 1H 2013 | % change | % currency impact |
% change in local currency |
|---|---|---|---|---|---|
| Household Care | 2,124 | 2,078 | 2 | (3) | 5 |
| Food & Beverages | 1,599 | 1,571 | 2 | (3) | 5 |
| Bioenergy | 1,050 | 873 | 20 | (6) | 26 |
| Agriculture & Feed | 919 | 949 | (3) | (5) | 2 |
| Technical & Pharma | 402 | 399 | 1 | (2) | 3 |
| Sales | 6,094 | 5,870 | 4 | (4) | 8 |
| (DKK million) | Q2 2014 | Q2 2013 | % change | % currency impact |
% change in local currency |
|---|---|---|---|---|---|
| Household Care | 1,044 | 1,065 | (2) | (3) | 1 |
| Food & Beverages | 802 | 809 | (1) | (4) | 3 |
| Bioenergy | 536 | 475 | 13 | (6) | 19 |
| Agriculture & Feed | 464 | 439 | 6 | (5) | 11 |
| Technical & Pharma | 215 | 237 | (9) | (2) | (7) |
| Sales | 3,061 | 3,025 | 1 | (4) | 5 |
| 2014 | 2013 | ||||||
|---|---|---|---|---|---|---|---|
| % change | |||||||
| (DKK million) | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 | Q2/Q2 |
| Household Care | 1,044 | 1,080 | 1,066 | 1,078 | 1,065 | 1,013 | (2) |
| Food & Beverages | 802 | 797 | 796 | 823 | 809 | 762 | (1) |
| Bioenergy | 536 | 514 | 540 | 496 | 475 | 398 | 13 |
| Agriculture & Feed | 464 | 455 | 382 | 337 | 439 | 510 | 6 |
| Technical & Pharma | 215 | 187 | 156 | 202 | 237 | 162 | (9) |
| Sales | 3,061 | 3,033 | 2,940 | 2,936 | 3,025 | 2,845 | 1 |
| (DKK million) | 1H 2014 | 1H 2013 | % change | % currency impact |
% change in local currency |
|---|---|---|---|---|---|
| Europe, Middle East & Africa | 2,264 | 2,167 | 4 | (1) | 5 |
| North America | 2,154 | 2,028 | 6 | (5) | 11 |
| Asia Pacific | 1,081 | 1,123 | (4) | (6) | 2 |
| Latin America | 595 | 552 | 8 | (10) | 18 |
| Sales | 6,094 | 5,870 | 4 | (4) | 8 |
| (DKK million) | Q2 2014 | Q2 2013 | % change | % currency impact |
% change in local currency |
|---|---|---|---|---|---|
| Europe, Middle East & Africa | 1,106 | 1,100 | 1 | - | 1 |
| North America | 1,109 | 1,051 | 6 | (4) | 10 |
| Asia Pacific | 537 | 576 | (7) | (6) | (1) |
| Latin America | 309 | 298 | 4 | (8) | 12 |
| Sales | 3,061 | 3,025 | 1 | (4) | 5 |
| 2014 | 2013 | ||||||
|---|---|---|---|---|---|---|---|
| (DKK million) | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 | % change Q2/Q2 |
| Europe, Middle East & Africa | 1,106 | 1,158 | 1,112 | 1,100 | 1,100 | 1,067 | 1 |
| North America | 1,109 | 1,045 | 930 | 905 | 1,051 | 977 | 6 |
| Asia Pacific | 537 | 544 | 542 | 569 | 576 | 547 | (7) |
| Latin America | 309 | 286 | 356 | 362 | 298 | 254 | 4 |
| Sales | 3,061 | 3,033 | 2,940 | 2,936 | 3,025 | 2,845 | 1 |
| (DKK million) | 1H 2014 | 1H 2013 |
|---|---|---|
| Net profit | 1,285 | 1,070 |
| Reversals of non-cash cost items Tax paid |
343 (206) |
807 (269) |
| Interest received | 4 | 1 |
| Interest paid | (29) | (33) |
| Cash flow before change in working capital | 1,397 | 1,576 |
| Change in working capital | ||
| (Increase)/decrease in receivables | 230 | (276) |
| (Increase)/decrease in inventories | (20) | (106) |
| Increase/(decrease) in trade payables and other liabilities | 1,590 | (176) |
| Increase/(decrease) in exchange gain/loss | 7 | (6) |
| Cash flow from operating activities | 3,204 | 1,012 |
| Investments | ||
| Purchase of intangible assets | - | (12) |
| Sale of intangible assets | 409 | - |
| Sale of property, plant and equipment | 10 | 2 |
| Purchase of property, plant and equipment | (206) | (342) |
| Cash flow from investing activities before acquisitions and | 213 | (352) |
| purchase of financial assets | ||
| Free cash flow before acquisitions and purchase of financial | ||
| assets | 3,417 | 660 |
| Business acquisitions and purchase of financial assets | (5) | (567) |
| Free cash flow | 3,412 | 93 |
| Financing activities | ||
| Borrowings | - | 261 |
| Repayments of borrowings | - | (3) |
| Purchase of treasury stock | (859) | - |
| Sale of treasury stock | 54 | 144 |
| Dividend paid | (788) | (690) |
| Cash flow from financing activities | (1,593) | (288) |
| Net cash flow | 1,819 | (195) |
| Unrealized gain/loss on currencies and financial assets, | ||
| included in cash and cash equivalents | (21) | (11) |
| Net change in cash and cash equivalents | 1,798 | (206) |
| Cash and cash equivalents at January 1 | 942 | 330 |
| Cash and cash equivalents at June 30 | 2,740 | 124 |
Undrawn committed credit facilities are DKK 4,118 million at June 30, 2014.
| Assets | |||
|---|---|---|---|
| (DKK million) | June 30, 2014 | June 30, 2013 | Dec. 31, 2013 |
| Completed IT development projects | 78 | 58 | 86 |
| Acquired patents, licenses and know-how | 1,856 | 2,175 | 1,754 |
| Goodwill | 1,048 | 902 | 1,022 |
| IT development projects in progress | - | 46 | 2 |
| Intangible assets | 2,982 | 3,181 | 2,864 |
| Land and buildings | 2,433 | 2,561 | 2,480 |
| Plant and machinery | 3,717 | 3,331 | 3,578 |
| Other equipment | 495 | 467 | 527 |
| Property, plant and equipment under construction | 327 | 879 | 550 |
| Property, plant and equipment | 6,972 | 7,238 | 7,135 |
| Deferred tax assets | 491 | 218 | 456 |
| Other financial assets (non-interest-bearing) | 18 | - | 14 |
| Investment in associate | 41 | 48 | 45 |
| Other receivables | 156 | 152 | 162 |
| Non-current assets | 10,660 | 10,837 | 10,676 |
| Raw materials and consumables | 287 | 274 | 276 |
| Goods in progress | 466 | 412 | 467 |
| Finished goods | 1,173 | 1,292 | 1,159 |
| Inventories | 1,926 | 1,978 | 1,902 |
| Trade receivables | 2,225 | 2,331 | 2,242 |
| Tax receivables | 264 | 235 | 151 |
| Other receivables | 255 | 311 | 301 |
| Receivables | 2,744 | 2,877 | 2,694 |
| Other financial assets (non-interest-bearing) | 43 | 14 | 87 |
| Cash at bank and in hand | 2,840 | 395 | 1,003 |
| Assets held for sale | - | - | 144 |
| Current assets | 7,553 | 5,264 | 5,830 |
| Assets | 18,213 | 16,101 | 16,506 |
| Liabilities and shareholders' equity | |||
|---|---|---|---|
| (DKK million) | June 30, 2014 | June 30, 2013 | Dec. 31, 2013 |
| Common stock | 639 | 639 | 639 |
| Other reserves | 124 | 371 | 290 |
| Retained earnings | 10,058 | 9,035 | 10,125 |
| Equity attributable to shareholders in | 10,821 | 10,045 | 11,054 |
| Novozymes A/S | |||
| Non-controlling interests | 12 | 14 | 12 |
| Shareholders' equity | 10,833 | 10,059 | 11,066 |
| Deferred tax liabilities | 946 | 1,110 | 956 |
| Provisions | 156 | 257 | 151 |
| Deferred income | 1,027 | - | - |
| Other non-current liabilities | 29 | - | - |
| Other financial liabilities (interest-bearing) | 1,339 | 1,718 | 1,716 |
| Other financial liabilities (non-interest-bearing) | 16 | 20 | 18 |
| Non-current liabilities | 3,513 | 3,105 | 2,841 |
| Other financial liabilities (interest-bearing) | 540 | 565 | 92 |
| Other financial liabilities (non-interest-bearing) | 42 | 73 | 13 |
| Provisions | 151 | 104 | 128 |
| Trade payables | 941 | 851 | 976 |
| Deferred income | 234 | - | - |
| Tax payables | 577 | 189 | 356 |
| Other payables | 1,382 | 1,155 | 1,034 |
| Current liabilities | 3,867 | 2,937 | 2,599 |
| Liabilities | 7,380 | 6,042 | 5,440 |
| Liabilities and shareholders' equity | 18,213 | 16,101 | 16,506 |
| Attributable to shareholders in Novozymes A/S | |||||||
|---|---|---|---|---|---|---|---|
| Currency | Cash | Non | |||||
| Common | translation | flow | Retained | controlling | |||
| (DKK million) | stock | adjustments | hedges | earnings | Total | interests | Total |
| Shareholders' equity at January 1, 2014 | 639 | 74 | 95 | 10,246 | 11,054 | 12 | 11,066 |
| Net profit for the period Other comprehensive income for the period |
(9) | (36) | 1,284 | 1,284 (45) |
1 | 1,285 (45) |
|
| Total comprehensive income for the period | - | (9) | (36) | 1,284 | 1,239 | 1 | 1,240 |
| Purchase of treasury stock | (859) | (859) | (859) | ||||
| Sale of treasury stock | 54 | 54 | 54 | ||||
| Write-down of common stock | - | - | |||||
| Dividend | (787) | (787) | (1) | (788) | |||
| Stock-based payment | 47 | 47 | 47 | ||||
| Tax related to equity items | 73 | 73 | 73 | ||||
| Changes in shareholders' equity | - | (9) | (36) | (188) | (233) | - | (233) |
| Shareholders' equity at June 30, 2014 | 639 | 65 | 59 | 10,058 | 10,821 | 12 | 10,833 |
| Shareholders' equity at January 1, 2013 | 650 | 428 | 4 | 8,473 | 9,555 | 13 | 9,568 |
| Net profit for the period | 1,069 | 1,069 | 1 | 1,070 | |||
| Other comprehensive income for the period | (71) | 10 | (61) | (61) | |||
| Total comprehensive income for the period | - | (71) | 10 | 1,069 | 1,008 | 1 | 1,009 |
| Sale of treasury stock | 144 | 144 | 144 | ||||
| Write-down of common stock | (11) | 11 | - | - | |||
| Dividend | (690) | (690) | - | (690) | |||
| Stock-based payment | 25 | 25 | 25 | ||||
| Tax related to equity items | 3 | 3 | 3 | ||||
| Changes in shareholders' equity | (11) | (71) | 10 | 562 | 490 | 1 | 491 |
| Shareholders' equity at June 30, 2013 | 639 | 357 | 14 | 9,035 | 10,045 | 14 | 10,059 |
| Q1 2014 | Novozymes LpHera® is a unique alpha-amylase for starch liquefaction that lowers liquefaction pH, reducing the need for pH-adjusting chemicals while improving crystallization and fermentation yields. |
|---|---|
| Q1 2014 | RONOZYME® MultiGrain (GT) is a xylanase and beta-glucanase enzyme solution for the animal feed market that offers superior formulation flexibility when using highly variable raw materials. |
| January 21, 2014 | Group financial statement for 2013 |
|---|---|
| February 10, 2014 | Novozymes and Monsanto complete closing of The BioAg Alliance |
| February 10, 2014 | Initiation of stock buyback program |
| February 26, 2014 | Novozymes A/S Annual Shareholders' Meeting 2014 |
| April 24, 2014 | Interim report for the first 3 months of 2014 |
| August 14, 2014 | Interim report for the first half of 2014 |
| October 23, 2014 | Interim report for the first 9 months of 2014 |
|---|---|
| January 20, 2015 | Group financial statement for 2014 |
| February 25, 2015 | Annual Shareholders' Meeting 2015 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.